LE180802 | Macular Degeneration Study


Help Medical Researchers

GET PAID $4990!

Enjoy Free WiFi & Food

APPLY NOW

Help us trial a new treatment for dry age-related macular degeneration (AMD) and juvenile onset macular degeneration, known as Stargardt disease (STGD).  Remuneration is based on completion of the in-house stay and all follow-up appointments.

Macular degeneration is the leading cause of major vision loss in Australia and can affect the ability to read, drive, recognise faces and perform activities that require detailed vision. Participating in this trial means you’ll be supporting world leading research into treatment for this condition. There are currently no approved treatments available for dry AMD or SGTD. 

Schedule

18 day in-house stay

Inclusion Criteria

  • Healthy Males and Females, aged between 18 and 65
  • Females must be of Non-Childbearing Potential (either Surgically Sterile or Postmenopausal)
  • Body Mass Index (BMI) between 18 – 30 kg/m2
  • Must be free from any clinically significant illness or disease
  • Participants must be non-smokers (Have not used any nicotine containing products in the last 28 days)
  • Participants must not have a history any severe reactions to medications
  • Participants must not have a history of Retinal Macular Edema or Stargardt Disease
  • Must not be currently participating in, or have participated in another clinical study within the last 6 weeks 
APPLY NOW

Spots are limited. Find out if you qualify today!

4 Appointments

Cohort IN-HOUSE FOLLOW UP APPOINTMENTS
Check-In Check-Out Day 18 Day 19 Day 21 Day 28
2 01-Jul 18-Jul 19-Jul 20-Jul 22-Jul 29-Jul

© Copyright 2019 Linear Clinical Research Ltd.

Cohort 2

Cohort IN-HOUSE FOLLOW UP APPOINTMENTS
Check-In Check-Out Day 18 Day 19 Day 21 Day 28
3 22-Jul 8-Aug 9-Aug 10-Aug 12-Aug 19-Aug

Cohort 3